The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin
Open accessAbstract
Rifampin is a cornerstone of modern antituberculosis therapy. However, rifampin's half-life of 3 h is believed to limit its utility for intermittent therapy, so new congeners with long half-lives are being developed. Using an in vitro pharmacokinetic-pharmacodynamic model of tuberculosis, we examined the relationships between rifampin exposure, microbial killing of log-phase-growth Mycobacterium tuberculosis , and suppression of resistance. Rifampin's microbial killing was linked to the area under the concentration-time curve-to-MIC ratio. The suppression of resistance was associated with the free peak concentration ( C max )-to-MIC ratio and not the duration that the rifampin concentration was above MIC. Rifampin prevented resistance to itself at a free C max /MIC ratio of ≥175. The postantibiotic effect duration was ≥5.2 days and was most closely related to the C max /MIC ratio ( r 2 = 0.96). To explain rifampin's concentration-dependent effect, we examined the kinetics of rifampin entry into M. tuberculosis . Rifampin achieved concentration-dependent intracellular steady-state concentrations within 15 min. Our results suggest that doses of rifampin higher than those currently employed would optimize the effect of rifampin, if patients could tolerate them. Another major implication is that in the design of new rifampin congeners for intermittent therapy, the important properties may include (i) the efficient entry of the rifamycin into M. tuberculosis , (ii) the achievement of a free C max /MIC of >175 that can be tolerated by patients, and (iii) a long postantibiotic effect duration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[64] The measurement of membrane potential and ΔpH in cells, organelles, and vesicles
Rottenberg, H. (1979) · Methods in Enzymology · doi:10.1016/0076-6879(79)55066-6 · Cited by 800
The mutant selection window and antimicrobial resistance
Drlica, K. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg269 · Cited by 437
Somoskovi, A., Parsons, L. M., & Salfinger, M. (2001) · Respiratory Research · doi:10.1186/rr54 · Cited by 373
Self-citationPharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis
Jayaram, R., Gaonkar, S., Kaur, P., Suresh, B. L., Mahesh, B. N., Jayashree, R., Nandi, V., Bharat, S., Shandil, R. K., Kantharaj, E., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2118-2124.2003 · Cited by 335
Gumbo, T., Louie, A., Deziel, M. R., Parsons, L. M., Salfinger, M., & Drusano, G. L. (2004) · The Journal of Infectious Diseases · doi:10.1086/424849 · Cited by 315
Self-citationRifampicin: A New Orally Active Rifamycin
Maggi, N., Pasqualucci, C. R., Ballotta, R., & Sensi, P. (1966) · Chemotherapy · doi:10.1159/000220462 · Cited by 270
Colangeli, R., Helb, D., Sridharan, S., Sun, J., Varma‐Basil, M., Hazbón, M. H., Harbacheuski, R., Megjugorac, N. J., Jacobs, W. R., Holzenburg, A., et al. (2005) · Molecular Microbiology · doi:10.1111/j.1365-2958.2005.04510.x · Cited by 188
Gumbo, T., Louie, A., Liu, W., Brown, D. L., Ambrose, P. G., Bhavnani, S. M., & Drusano, G. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00185-07 · Cited by 163
Self-citationINFLUENCE OF BINDING ON THE PHARMACOLOGIC ACTIVITY OF ANTIBIOTICS
Kunin, C. M., Craig, W. A., Kornguth, M. L., & Monson, R. A. (1973) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1973.tb20483.x · Cited by 146
Metabolism and Pharmacokinetics of the Antibiotic Rifampin
Kenny, M. T., & Strates, B. S. (1981) · Drug Metabolism Reviews · doi:10.3109/03602538109011084 · Cited by 136
Viveiros, M., & Amaral, L. (2001) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00343-5 · Cited by 134
Interventions for tuberculosis control and elimination.
Rieder, H. L., & Disease, L. (2002) · Cited by 129
Dong, Y., Zhao, X., Kreiswirth, B. N., & Drlica, K. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2581-2584.2000 · Cited by 128
Siddiqi, N., Pathak, N., Banerjee, S., Ahmed, N., Katoch, V. M., Hasnain, S. E., & Das, R. (2004) · Infection · doi:10.1007/s15010-004-3097-x · Cited by 123
Isoniazid-Induced Transient High-Level Resistance in Mycobacterium tuberculosis
Viveiros, M., Portugal, I., Bettencourt, R., Victor, T. C., Jordaan, A. M., Leandro, C., Ordway, D. J., & Amaral, L. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.2804-2810.2002 · Cited by 110
Piddock, L. J. V., Williams, K. J., & Ricci, V. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.2.159 · Cited by 109
Significance of Serum Protein and Tissue Binding of Antimicrobial Agents
Craig, W. A., & Kunin, C. M. (1976) · Annual Review of Medicine · doi:10.1146/annurev.me.27.020176.001443 · Cited by 104
Gumbo, T., Louie, A., Liu, W., Ambrose, P. G., Bhavnani, S. M., Brown, D. L., & Drusano, G. L. (2006) · The Journal of Infectious Diseases · doi:10.1086/510247 · Cited by 101
Self-citationLee, C.-N., & Heifets, L. B. (1987) · American Review of Respiratory Disease · doi:10.1164/ajrccm/136.2.349 · Cited by 91
Pharmacokinetics of Rifapentine at 600, 900, and 1,200 mg during Once-Weekly Tuberculosis Therapy
WEINER, M. H., BOCK, N. N., Peloquin, C. A., Burman, W. J., Khan, A., Vernon, A. A., Zhao, Z., Weis, S. E., Sterling, T. R., Hayden, K., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200311-1612oc · Cited by 89
Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative.
Arioli, V., BERTI, M., CARNITI, G., Randisi, E., Rossi, E., & SCOTTI, R. (1981) · The Journal of Antibiotics · doi:10.7164/antibiotics.34.1026 · Cited by 77
Gupta, A. K., Chauhan, D. S., Srivastava, K., Das, R., Batra, S., Mittal, M., Goswami, P., Singhal, N., Sharma, V. D., Venkatesan, K., et al. (2006) · PubMed · Cited by 75
Guerlava, P., Izac, V., & Tholozan, J.-L. (1998) · Current Microbiology · doi:10.1007/pl00006756 · Cited by 62
Drusano, G. L., D’Argenio, D. Z., Preston, S. L., Barone, C., Symonds, W., LaFon, S. W., Rogers, M., Prince, W., Bye, A., & Bilello, J. A. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1655-1659.2000 · Cited by 60
Self-citationAntimicrobial Therapy of Tuberculosis: Justification for Currently Recommended Treatment Regimens
Mitchison, D. A. (2004) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2004-829503 · Cited by 59
Purification and properties of DNA-dependent RNA polymerase from Mycobacterium tuberculosis H37Rv
Harshey, R. M., & Ramakrishnan, T. V. (1976) · Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis · doi:10.1016/0005-2787(76)90040-x · Cited by 36
Rifampicin activity "in vitro" and in established tuberculosis in mice.
VERBIST, L. (1969) · PubMed · Cited by 27
Cited by
Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., Furin, J., Nardell, E. A., London, L., Lessem, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30079-6 · Cited by 684
Self-citationTherapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update
Alsultan, A., & Peloquin, C. A. (2014) · Drugs · doi:10.1007/s40265-014-0222-8 · Cited by 444
Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes
Pasipanodya, J. G., McIlleron, H., Burger, A., Wash, P. A., Smith, P., & Gumbo, T. (2013) · Journal of Infectious Diseases · doi:10.1093/infdis/jit352 · Cited by 444
Self-citationBoeree, M. J., Heinrich, N., Aarnoutse, R., Diacon, A. H., Dawson, R., Rehal, S., Kibiki, G. S., Churchyard, G., Sanne, I., Ntinginya, N. E., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30274-2 · Cited by 379
A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
Boeree, M. J., Diacon, A. H., Dawson, R., Narunsky, K., du Bois, J., Venter, A., Phillips, P. P. J., Gillespie, S. H., McHugh, T. D., Hoelscher, M., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201407-1264oc · Cited by 309
Metadata
- Authors
- Gumbo, T., Louie, A., Deziel, M. R., Liu, W., Parsons, L. M., Salfinger, M., & Drusano, G. L.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2007-11
- Volume
- 51
- Issue
- 11
- Pages
- 3781-3788
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2117466548
- Cited by
- 345
- References
- 27
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.